Chromosomal translocations that juxtapose the androgen-sensitive transmembrane protease, serine 2 (TMPRSS2) gene promoter to the oncogenic ETS-family transcription factor ERG result in excessive ERG overexpression in approximately 50% of prostate cancer (PCa) patients. Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important regulators of cancer. Through bioinformatics analysis of ChIP-Seq ERG data and miRNA expression profiling data we nominated miR-200c as a direct target of ERG. Experimentation of PCa cells with ERG overexpression or knockdown demonstrated that ERG directly repressed miR-200c expression by physically binding to the erythroblast transformation-specific (ETS) motif within its promoter. Consequently, miR-200c was downregulated in ERG-positive PCa, and miR-200c target gene expression was restored. In addition, the expression pattern of miR-200c target genes predicted ERG status in clinical PCa specimens. Furthermore, miR-200c was found to be important in modulating ZEB1 upregulation by ERG. Most importantly, miR-200c reconstitution fully reversed ERG-induced epithelial-to-mesenchymal transition (EMT), cell migration and invasion. Therefore, our study report miR-200c as the first miRNA target of ERG and a critical inhibitor of PCa cell motility. Therapeutic delivery of miR-200c may provide personalized treatment for patients with the molecular subtype of PCa that harbors TMPRSS2-ERG gene fusions.
INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer and a leading cause of cancer-related deaths in American men. 1 While organ-confined tumors are largely treatable, metastatic diseases are inevitably lethal. During the initiation and progression of prostate cancer, many genetic mutations and deregulation occur and accumulate. Among these, chromosomal translocations that juxtapose the androgen-sensitive promoter of the transmembrane protease, serine 2 (TMPRSS2) gene to the coding region of the oncogenic erythroblast transformationspecific (ETS) family transcription factor ERG (v-ets avian erythroblastosis virus E26 oncogene homolog), termed TMPRSS2-ERG gene fusions, have been found in 40-80% of PCa. [2] [3] [4] [5] In addition to PCa, recurrent gene fusions involving the ERG gene have also been previously reported in Ewing's sarcoma and acute myeloid leukemia. 6, 7 ERG has been shown to induce multiple oncogenic processes, out of which the most commonly reported are its induction of epithelial-to-mesenchymal transition (EMT) and increase of cell motility. [8] [9] [10] Numerous studies have in the past few years examined the molecular mechanisms and downstream mediators of these oncogenic roles of ERG. Such studies have yielded highly significant findings showing ERG regulation of pathways that are highly important in PCa, including the androgen receptor (AR) pathway, 11, 12 Wnt/TCF signal transduction, [13] [14] [15] and polycomb group proteins and cell self-renewal. 11, 16 While it is clear that these molecular pathways are important mediators of ERG-induced oncogenesis in PCa, very few studies have attempted to examine how ERG might regulate microRNAs, which are increasingly recognized as potent regulators of gene expression and cellular processes.
A microRNA (miRNA) is a small non-coding RNA that is usually 18-22 nucleotides long. They are expressed endogenously in cells and, to date, more than 2000 unique mature miRNAs have been found in human cells. The miRNAs negatively regulate gene expression through mRNA degradation or translational repression via binding to the 3 0 UTR of target genes. 17 Since miRNAs can target and repress a large set of genes, small changes in miRNA levels can have major effects on cellular processes and diseases, including cancer. 18, 19 The expression levels of miRNAs are thus tightly regulated. Global miRNA profiling in human cancer patient samples has identified a large set of miRNAs that are differentially expressed in cancer. 20, 21 These miRNAs are de-regulated often through mechanisms such as promoter methylation, genomic deletion, histone modifications and upstream protein alteration. 20, 22, 23 In particular, several miRNAs such as miR-34, miR-145 and miR-31 have been shown to be downregulated in PCa patients. They regulate important factors such as c-Myc, stem-cell markers and AR, thereby controlling PCa progression. [24] [25] [26] There are about 30 such miRNAs that have been explored in PCa to determine their downstream genes and how they contribute to PCa initiation, progression and metastasis. 27 As miRNAs play important roles in gene regulation and they are often dys-regulated in cancer, it is plausible that some miRNAs may be targets of ERG, and their loss may convey some of the ERG-induced prostate tumorigenesis. Surprisingly, although many studies have investigated the downstream genes of ERG, very few 1 Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA and studies have examined the miRNAs that are regulated by ERG. Up to date, there are only two studies that have examined correlation between ERG and miRNAs in PCa. In one study, Hart et al. 28 showed that miR-145 inhibits ERG expression by directly targeting its 3 0 UTR. Loss of miR-145 may provide a TMPRSS2-ERG gene fusion-independent means to ERG upregulation in PCa. In the other study, through analysis of PCa samples, Gordanpour et al. 29 found that miR-221 is downregulated in patients with tumors bearing TMPRSS2-ERG gene fusions. However, no mechanistic studies were carried out to determine whether and how ERG regulates miR-221 expression. To fill in this gap, in this study we carried out a comprehensive bioinformatics analysis to identify miRNAs that are downstream of ERG and nominate miR-200c as a robust and important ERG-regulated miRNA.
The miR-200c is a member of the miR-200 family of miRNAs that also include miR-200a, miR-200b, miR-141 and miR-429. miRNA expression profiling has revealed miR-200c to be downregulated in metastatic vs primary tumors. 30 The loss of miR-200c is linked to poor differentiation and stem cell-like cancer cells 31 and is regulated by DNA methylation, oncogene activation or loss of tumor suppressor genes such as p53. [32] [33] [34] [35] Functional studies have clearly demonstrated essential roles of miR-200c in suppressing EMT and inhibiting metastasis of various cancer types. 36, 37 Mechanistically, this is mediated by reciprocal repression of miR200c and ZEB1, a critical mediator and activator of EMT. 33, 38 Reconstitution or expression of miR-200c has thus been attempted, which was shown to inhibit EMT, reverse drug resistance and sensitize cancer cells to treatments. 37, 39, 40 Despite this well-established importance of miR-200c in various cancer types, only very few studies have explored miR-200c in PCa. Specifically, one study has demonstrated miR-200c as a mediator of EZH2 and BMI1, which are oncogenes highly upregulated in metastatic PCa, suggesting that miR-200c may also play important functions in PCa. 41 In this study, by integrating ERG ChIP-Seq data with miRNA expression data profiling PCa cells with or without ERG dysregulation, we nominated miR-200c as an ERG target miRNA. Using gene-specific primers, we demonstrated that ERG directly repressed miR-200c expression by binding to the ETS motif within its promoter. We further showed that this regulation is relevant in human PCa through analysis of gene expression in clinical specimens. Moreover, using functional assays we illustrated an important role of miR-200c in mediating ERG-induced EMT and cell motility through regulation of ZEB1 expression.
RESULTS

microRNA expression profiling nominated miR-200c as a downstream target of ERG
In previous studies, we have carried out ERG ChIP-Seq in PCa cells and have discovered many ERG-bound target genes. 11 As miRNAs are increasingly recognized as important regulators of gene expression and cellular processes, we examined whether ERG protein binds to the cis-regulatory elements of miRNAs. Bioinformatics analyses were carried out to scan ERG-binding events within 5 kb upstream of all miRNA genes reported. ERG ChIP-Seq data derived from the ERG-positive VCaP cells and the LNCaP cells with stable ectopic ERG overexpression (LNCaP þ ERG) were utilized. Our analysis revealed a total of 140 and 115 miRNAs that harbor at least one ERG-binding event within their regulatory regions in the VCaP and LNCaP þ ERG cells, respectively (Supplementary Tables S1 and S2 ). These data suggested that ERG might be able to transcriptionally regulate the expression of miRNAs by binding to their cis-regulatory elements. Next, we attempted to identify these ERG-regulated miRNAs.
We utilized the Exiqon miRCURY LNA Array miRNA profiling (Woburn, MA, USA) to obtain global expression profiles of miRNA in control cells and cells with ERG dys-regulation. We first analyzed the effect of ectopic ERG overexpression in LNCaP cells, which do not express endogenous ERG. Through miRNA profiling we found that while a majority of the miRNAs was not differentially expressed, the expression of some miRNAs was altered by ERG ( Figure 1a ). The fold of alteration was generally low, which is consistent with the previous notion that miRNAs are tightly regulated and that small changes in miRNAs may yield significant downstream effects. After removing the miRNAs that were expressed at undetectably low levels, we obtained a list of 114 and 18 miRNAs that were, respectively, repressed and induced following ERG overexpression in LNCaP cells (Supplementary Table S3 ).
As the effect of ectopic ERG overexpression may be less physiological, we on the other hand carried out ERG knockdown using RNA interference in the ERG-positive VCaP cells. Using miRNA profiling we identified 117 and 40 miRNAs that were respectively upregulated or downregulated following ERG knockdown (Figure 1b ; Supplementary Table S4 ). Remarkably, there was approximately 50% overlap between miRNAs that were repressed by ERG in LNCaP cells and those that were restored by ERG knockdown in VCaP cells (Figures 1c and d) . Similarly, about 50% of miRNAs that were induced by ERG in LNCaP cells were repressed by ERG knockdown in VCaP cells (Supplementary Figure S1 ). These overlapping miRNAs represent a robust set of candidate ERG target miRNAs that warrant further characterization. In this study, we chose to focus on ERG-repressed miRNAs as they might provide unique opportunities for miRNA delivery or reconstitution as therapeutics for the molecular subtype of PCa that harbor TMPRSS2-ERG gene fusions.
To identify miRNAs that are directly regulated by ERG, we integrated the ERG-regulated miRNA gene expression data with ERG-bound miRNAs identified using ChIP-Seq data (Supplementary  Tables S1 and S2 ). Out of the 61 robust ERG-repressed miRNAs, 16 and 9 were directly bound by ERG protein in VCaP and LNCaP þ ERG cells, respectively (Figures 1c,d) . Out of these, eight overlapped. Out of these eight miRNAs, miR-200c has been previously shown to play important tumor suppressive roles by inhibiting cell motility and EMT. 36, 38 Repression of miR-200c could lead to increased cell motility and EMT, a function of ERG that has been extensively demonstrated. 8, 10 In addition, even though miR200c's functional roles and downstream targets have been widely studied in various cancer types, studies of miR-200c in PCa have been very limited. Therefore, we decided to focus this study on characterizing miR-200c as an ERG-regulated miRNA in PCa.
ERG directly regulates miR-200c expression To validate our computational results nominating miR-200c as a direct target of ERG, we utilized miRNA TaqMan Assay to verify ERG regulation of miR-200c expression using gene-specific primers. We first carried out ERG knockdown via RNA interference (Figure 2a) . Western blot analysis confirmed that ERG protein was reduced by more than 80%. QRT-PCR analysis demonstrated that miR-200c expression was significantly upregulated following ERG knockdown, and so did previously reported ERG-repressed genes such as PSA and TMPRSS2. 11 On the other hand, we carried out ERG overexpression in LNCaP cells, which was confirmed by western blot analysis (Figure 2b ). Concordantly, qRT-PCR analysis revealed that ERG inhibited the expression of miR-200c as well as known ERG-repressed target genes such as PSA and TMPRSS2. To further verify this in additional prostate cell models, we overexpressed ectopic ERG in a panel of PCa cell lines, including LAPC4, DU145 and BPH1. First, we verified ERG overexpression using immunoblot analysis (Figure 2c ). Then, miR-200c level was tested using TaqMan miRNA assay, and we found that miR-200c expression was drastically decreased by ERG in all of these cell lines (Figure 2d (Figure 3b ), which has been previously shown to be occupied by ERG. 11 In addition, using ChIP-PCR we demonstrated that ectopic ERG overexpression in LNCaP cells resulted in a remarkable increase of ERG occupancy on the miR-200c promoter and PSA enhancer (Figure 3c ). By contrast, ERG binding on KIAA0066, a negative control gene, was only marginally increased. To determine whether this holds true in clinical PCa specimens, we carried out ERG ChIP in several human PCa tissues that harbor the TMPRSS2-ERG gene fusion. Due to the limited amount of tissue and thus ChIP-enriched DNA, linear amplification of the DNA was carried out along with an equal amount of input DNA. ChIP-PCR experiment showed that miR200c promoter and PSA enhancer were significantly enriched in the ERG-pulldown DNA relative to the input (Figure 3d ). Therefore, ERG directly occupied miR-200c promoter in both PCa cell lines as well as human PCa tissues.
Next, we attempted to address whether this ERG occupancy at the cis-regulatory element of miR-200c can indeed lead to regulation of the promoter activity. Examination of the sequence of miR-200c upstream promoter revealed a highly conserved ETS motif at the center of the ERG-binding peak that is 1 kb upstream of the miR-200c promoter (Figure 3e) . We thus cloned a 1-kb DNA fragment that flanks this ERG binding event into a luciferase reporter vector. Next, we performed luciferase reporter assays to determine how ERG regulates the activity of this promoter. Through serial dilutions of ERG adenovirus, we showed that increasing the amount of ectopic ERG overexpression in LNCaP cells resulted in a dose-dependent gradual decrease of miR-200c promoter activity (Supplementary Figure S2B) . This was further verified in another independent PCa cell line 22Rv1, wherein luciferase assay showed that ERG drastically inhibited the activities Figure S2C) . To determine whether this repression is indeed mediated by the ETS motif, we generated a mutant miR200c promoter construct that has two core nucleotides with the motif mutated. Luciferase reporter assay illustrated that while ERG overexpression in LNCaP cells significantly inhibited miR-200c wild-type promoter and PSA promoter/enhancer activities, the activity of the miR-200c mutant promoter was only marginally repressed ( Figure 3f ). Taken together, our data demonstrated that ERG represses miR-200c through direct binding and regulation of its cis-regulatory element.
The miR-200c target genes predict ERG status in prostate cancer We next took our study one step further and examined whether ERG regulation of miR-200c is physiologically relevant in clinical specimens. Since ERG inhibits miR-200c expression, we expect to see miR-200c downregulation in TMPRSS2-ERG fusion-positive human PCa. We analyzed a previously published microarray data set that profiled both mRNA and miRNA expression in matched set of samples. 42 We limited our analysis to localized PCa as previous studies have extensively shown miR-200c downregulation in metastatic diseases, while TMPRSS2-ERG gene fusions, by contrast, are present in similar percentages in localized and metastatic PCa. Based on the level of ERG transcript, we stratified the PCa specimens into 2 categories: ERG-positive and ERG-negative (Supplementary Figure S3) . Our analysis revealed that miR-200c was expressed at significantly lower levels in the ERG-positive PCa tissues relative to the ERG-negative ones ( Figure 4a ).
As there are very few microarray data sets that have profiled mRNA and miRNA in matched clinical specimens, our analysis of ERG and miR-200c in human samples were largely limited. To address this, we attempted to obtain a set of signature genes that are downstream to miR-200c, which can then be analyzed in more independent data sets. We thus conducted expression microarray profiling of LNCaP cells with control or miR-200c overexpression. Microarray analysis revealed a total of 37 and 56 genes, respectively, that were induced and repressed by miR-200c by at least two fold. We chose the miR-200c-repressed genes for further analysis as they are more likely to represent direct effects of miR-200c expression. We expected the expression of these genes to be upregulated by ERG, since ERG inhibits miR-200c. To test this, we carried out gene set enrichment analysis (GSEA) of this gene set in a microarray data set where we profiled LNCaP cells with control or ERG overexpression. GSEA revealed that miR200c-repressed genes were significantly enriched for upregulation in ERG-overexpressing LNCaP cells (Figure 4b ). These genes thus comprise a miR-200c signature that is responsive to ERG expression.
To determine whether these miR-200c signature genes are responsive to ERG regulation in clinical specimens, we asked whether their expression as a whole can accurately predict the ERG expression level in human PCa. Utilizing publically available microarray data sets that have profiled a large number of human PCa tissues, we obtained the expression profiles of the miR-200c signature genes. Samples were then clustered based on the expression patterns of these genes. Remarkably, we found the miR-200c signature genes were able to separate PCa into ERGnegative and ERG-positive categories in two independent PCa Figures 4c,d) . 25, 43 ERG expression levels were significantly different (P ¼ 8.2E À 13 and P ¼ 0.00015 for Grasso et al. and Lapointe et al., respectively) between the 'ERG-negative' and 'ERG-positive' samples stratified by the miR-200c signature genes. These results supported the clinical relevance of our findings in human PCa.
ERG induces ZEB1 expression through modulating miR-200c level Previous studies have extensively shown miR-200c as a critical suppressor of EMT and thus an inhibitor of cell motility and tumor metastasis. 36, 37, [44] [45] [46] This activity is in direct contrast to that of ERG, which induces EMT and cell motility. Studies of other cancer types have also revealed that this functionality of miR-200c is at least in part mediated by its reciprocal repression of the ZEB1 gene. miR-200c mediates ERG-induced cell motility ERG has been extensively shown to induce tumorigenesis through increasing cell invasion and migration with a mesenchymal phenotype. 8, 11, 12, 47, 48 To study the role of miR-200c in regulating these functions, we examined the ERG-miR-200c-ZEB1 axis in the DU145 PCa cell line that is readily feasible for cell migration and cell invasion assays. DU145 cells with stable ERG overexpression were generated (Supplementary Figure S5A) . Concordant with the results shown in Figure 5 , ERG overexpression significantly induced ZEB1 expression, while miR-200c reconstitution in these cells blocked this increase (Figure 6a ). In addition, western blot analysis showed that ERG inhibited the expression of epithelial marker E-cadherin but induced mesenchymal markers ZEB1 and Vimentin. Most importantly, these changes were markedly reversed by miR-200c overexpression in the DU145 þ ERG stable cells (Figure 6b ). Therefore, miR-200c suppresses ERG-induced PCa cell transformation.
As mesenchymal transition is causatively related to increased cell motility, we next examined whether miR-200c affects ERGinduced cell motility. Boyden chamber assay was utilized to monitor cell invasion, while wound healing assay was carried out to determine cell migration. Being consistent with previous reports, ERG overexpression alone greatly induced DU145 cell invasion and migration (Figures 6c,d) Figure S5C) . Therefore, our data demonstrated that miR-200c reconstitution is able to fully invert PCa cell transformation and cell motility caused by ERG.
DISCUSSION
Since the initial discovery of its involvement in recurrent gene fusions in 40-80% of PCa, the ERG gene has been extensively studied in terms of its tumorigenic function. 2 The most prominent role of ERG that has been consistently shown in numerous studies is its ability to increase cell migration and invasion via abrogating prostate epithelial differentiation and inducing EMT and motilityassociated genes such as MMPs. 8, 11, 49, 50 Many target genes and molecular pathways have been implicated in mediating the oncogenic roles of ERG, including AR, Wnt signaling, NF-kB and PARP1. 11, 14, 51, 52 However, studies of miRNAs in the context of this gene fusion are very limited. Only one study has described one miRNA, miR-221, to be downregulated in the fusion-positive PCa, while potential regulatory mechanisms accountable for this association were not investigated. 29 As miRNAs are increasingly shown to be vital regulators of cellular behavior as well as diseases including cancer, it is highly important to identify and characterize miRNAs that are regulated by ERG. In this study, we utilized bioinformatics approaches to integrate ERG ChIP-Seq data with miRNA profiling data to identify a robust set of miRNAs whose cisregulatory elements were occupied by ERG and that were differentially expressed upon ERG dys-regulation in PCa cells (Supplementary Tables S1-S4 and Figure 1) . Although in this study we chose to focus on miR-200c, many of these miRNAs may similarly play significant roles in ERG-mediated cellular processes and PCa progression, which can be important areas for future studies. Cell invasion was carried out using Boyden chamber assay. Briefly, DU145 cells were plated in the top chamber above matrigel and incubated for 16 h to invade through the membrane. The invaded cells were then stained and photographed. Experiments were repeated at least 3 times and one representative result is shown. (d) Ectopic ERG overexpression increased DU145 cell migration, which was reverted by miR-200c expression. Cells were plated at the same density and a wound was then made by scratching. Images were taken at 0, 14, and 23 h. Experiments were repeated at least 3 times and one representative result is shown.
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The miR-200c gene is one of the best-studied miRNAs. It was found to be downregulated in various metastatic types of solid tumors when compared with primary tumors. 30 Extensive research has shown miR-200c to play critical roles in inhibiting EMT, cell motility and tumor metastasis of various cancer types such as breast, lung and colon cancers. [33] [34] [35] [36] Surprisingly, less than a handful of papers have explored miR-200c in PCa to some degree, linking miR-200c to docetaxel resistance, polycomb group protein regulation and Notch signaling. 41, 45, 46 Nevertheless, the regulation and function of miR-200c in PCa remains largely to be examined. Our study is the first to demonstrate that miR-200c is a direct target of ERG and is repressed in ERG fusion-positive PCa. In addition, we showed that miR-200c loss mediates ERG-induced EMT and cell motility. Our data suggest that therapeutic delivery of miR-200c may provide targeted treatment of patients with ERG fusion-positive PCa.
In the present study, we showed that ZEB1 is a target gene of miR-200c in PCa, being consistent with observations previously reported in other cancer types. 33, 38 In addition, we showed that miR-200c reverted ERG-induced oncogenesis by repressing ZEB1. However, miR-200c might affect the expression of many downstream molecules in addition to ZEB1. Considering the essential tumor-suppressive roles of miR-200c in PCa as demonstrated in our study, it warrantees further investigation of miR-200c downstream genes or pathways in PCa. It will be of great interest for future studies to determine the expression profile of miR-200c during different stages of PCa progression and in various molecular subtypes and investigate how miR-200c may regulate other important disease pathways of PCa, such as AR signaling and Wnt pathways. In addition, it will be highly impactful to examine how miR-200c reconstitution alters these pathways and thus affects drug response and treatments of PCa. These will be important lines for future studies.
In summary, this study identified many miRNAs that are potentially regulated by TMPRSS2-ERG gene fusions, thereby offering a new research paradigm that may provide novel mechanisms to ERG-induced prostate tumorigenesis. In addition, these miRNAs may be in general involved in PCa progression and thus warrantee future investigation. As increasing evidence has suggested that circulating miRNAs may be useful biomarkers for clinical diseases, future studies of these miRNAs may potentially provide noninvasive diagnostic or prognostic tools. This study characterized the first ERG-target miRNA gene miR-200c and suggested that miR-200c reconstitution may provide targeted therapies for patients with TMPRSS2-ERG gene fusion-positive PCa. MicroRNA profiling and bioinformatics analysis Total RNA was extracted using TRIzol following the manufacturer's protocol (Invitrogen). MicroRNA profiling and data extraction were performed using miRCURY LNA array (Exiqon) after confirmation of RNA integrity. Enrichment of gene sets was analyzed using the Gene Set Enrichment Analysis tool (Broad Institute, Cambridge, MA, USA) as previously described. 53 Expression of miR-200c signature genes in the publically available data set was queried using the Oracle database. 25, 43 Clustering of clinical specimens was carried out using Cluster software and visualized using TreeView.
MATERIALS AND METHODS
Western blots and antibodies
Protein extraction and western blot analysis were performed using the standard protocol. Antibodies used were as follows: anti-GAPDH (ab9385, Abcam, Cambridge, MA, USA), anti-ERG (963A, CPRD for western blot), anti-ERG (sc-354x, Santa Cruz, Santa Cruz, CA, USA for ChIP), anti-E-cadherin (3195P, Cell signaling, Danvers, MA, USA), anti-ZEB1 (3396P, Cell signaling) and anti-vimentin (3932P, Cell signaling).
ChIP, ChIP-qPCR, quantitative qRT-PCR, TaqMan miRNA assay ChIP was carried out as previously described. 54 Quantitative PCR was performed in Applied Biosystems StepOne Plus Real Time PCR system using GoTaq qPCR Master Mix 2X (Promega) for genes and TaqMan microRNA assays for miRNAs (Applied Biosystems, Carlsbad, CA, USA). All primers were designed using primer 3 and synthesized by Integrated DNA Technologies (Coralville, IA, USA) (Supplementary Table S5 ).
Functional assays
Luciferase assay was performed as previously described. 55 In brief, for promoter luciferase assay, pGL4.1[luc2]-miR200c or pGL4.1[luc2]-miR200c mutants were transfected with Renilla internal control. After 6 h, either LacZ or ERG adenovirus was added, then incubated for 48 h before assays were performed. For 3 0 UTR luciferase assay, pMIR-REPORT or pMIR-REPORT-ZEB1 was co-transfected with either control or miR-200c overexpression vector and Renilla internal control. Then, cells were incubated for 48 h before assays were performed. Wound healing and invasion assays were performed as previously described using DU145 control and ERG stable cell line infected with either empty vector or miR200c expressing retrovirus. 55 For wound healing assay, images were taken 0, 14 and 23 h after wound was made using Olympus CKX41. For invasion assay, cells were stained with crystal violet for images and invaded cells were counted using ImageJ (NIH, Bethesda, MD, USA).
